Cargando…
Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis
Immunotherapy has yielded impressive results, but only for a minority of patients with cancer. Therefore, new approaches that potentiate immunotherapy are a pressing medical need. Ferroptosis is a newly described type of programmed cell death driven by iron-dependent phospholipid peroxidation via Fe...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490994/ https://www.ncbi.nlm.nih.gov/pubmed/32919370 http://dx.doi.org/10.1016/j.isci.2020.101499 |
_version_ | 1783582131454214144 |
---|---|
author | Ruiz-de-Angulo, Ane Bilbao-Asensio, Marc Cronin, James Evans, Stephen J. Clift, Martin J.D. Llop, Jordi Feiner, Irene V.J. Beadman, Rhiannon Bascarán, Kepa Zamacola Mareque-Rivas, Juan C. |
author_facet | Ruiz-de-Angulo, Ane Bilbao-Asensio, Marc Cronin, James Evans, Stephen J. Clift, Martin J.D. Llop, Jordi Feiner, Irene V.J. Beadman, Rhiannon Bascarán, Kepa Zamacola Mareque-Rivas, Juan C. |
author_sort | Ruiz-de-Angulo, Ane |
collection | PubMed |
description | Immunotherapy has yielded impressive results, but only for a minority of patients with cancer. Therefore, new approaches that potentiate immunotherapy are a pressing medical need. Ferroptosis is a newly described type of programmed cell death driven by iron-dependent phospholipid peroxidation via Fenton chemistry. Here, we developed iron oxide-loaded nanovaccines (IONVs), which, chemically programmed to integrate iron catalysis, drug delivery, and tracking exploiting the characteristics of the tumor microenvironment (TME), improves immunotherapy and activation of ferroptosis. The IONVs trigger danger signals and use molecular disassembly and reversible covalent bonds for targeted antigen delivery and improved immunostimulatory capacity and catalytic iron for targeting tumor cell ferroptosis. IONV- and antibody-mediated TME modulation interfaced with imaging was important toward achieving complete eradication of aggressive and established tumors, eliciting long-lived protective antitumor immunity with no toxicities. This work establishes the feasibility of using nanoparticle iron catalytic activity as a versatile and effective feature for enhancing immunotherapy. |
format | Online Article Text |
id | pubmed-7490994 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Elsevier |
record_format | MEDLINE/PubMed |
spelling | pubmed-74909942020-09-21 Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis Ruiz-de-Angulo, Ane Bilbao-Asensio, Marc Cronin, James Evans, Stephen J. Clift, Martin J.D. Llop, Jordi Feiner, Irene V.J. Beadman, Rhiannon Bascarán, Kepa Zamacola Mareque-Rivas, Juan C. iScience Article Immunotherapy has yielded impressive results, but only for a minority of patients with cancer. Therefore, new approaches that potentiate immunotherapy are a pressing medical need. Ferroptosis is a newly described type of programmed cell death driven by iron-dependent phospholipid peroxidation via Fenton chemistry. Here, we developed iron oxide-loaded nanovaccines (IONVs), which, chemically programmed to integrate iron catalysis, drug delivery, and tracking exploiting the characteristics of the tumor microenvironment (TME), improves immunotherapy and activation of ferroptosis. The IONVs trigger danger signals and use molecular disassembly and reversible covalent bonds for targeted antigen delivery and improved immunostimulatory capacity and catalytic iron for targeting tumor cell ferroptosis. IONV- and antibody-mediated TME modulation interfaced with imaging was important toward achieving complete eradication of aggressive and established tumors, eliciting long-lived protective antitumor immunity with no toxicities. This work establishes the feasibility of using nanoparticle iron catalytic activity as a versatile and effective feature for enhancing immunotherapy. Elsevier 2020-08-26 /pmc/articles/PMC7490994/ /pubmed/32919370 http://dx.doi.org/10.1016/j.isci.2020.101499 Text en © 2020 The Authors http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). |
spellingShingle | Article Ruiz-de-Angulo, Ane Bilbao-Asensio, Marc Cronin, James Evans, Stephen J. Clift, Martin J.D. Llop, Jordi Feiner, Irene V.J. Beadman, Rhiannon Bascarán, Kepa Zamacola Mareque-Rivas, Juan C. Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis |
title | Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis |
title_full | Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis |
title_fullStr | Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis |
title_full_unstemmed | Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis |
title_short | Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis |
title_sort | chemically programmed vaccines: iron catalysis in nanoparticles enhances combination immunotherapy and immunotherapy-promoted tumor ferroptosis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7490994/ https://www.ncbi.nlm.nih.gov/pubmed/32919370 http://dx.doi.org/10.1016/j.isci.2020.101499 |
work_keys_str_mv | AT ruizdeanguloane chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis AT bilbaoasensiomarc chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis AT croninjames chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis AT evansstephenj chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis AT cliftmartinjd chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis AT llopjordi chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis AT feinerirenevj chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis AT beadmanrhiannon chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis AT bascarankepazamacola chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis AT marequerivasjuanc chemicallyprogrammedvaccinesironcatalysisinnanoparticlesenhancescombinationimmunotherapyandimmunotherapypromotedtumorferroptosis |